 PHILADELPHIA, PA, Jan. 04, 2022 GLOBE NEWSWIRE -- Vallon Pharmaceuticals, Inc. NASDAQ: VLON, Vallon or the Company, a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system CNS disorders, announced today that David Baker, President Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022. 